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doi:10.1016/j.tcmj.2011.12.002A 13-year-old boy was brought to a genetic counseling clinic for
a tuberous sclerosis complex (TSC) gene test by hismother whowas
affected by TSC. The boy’s mother had facial angioﬁbromas,
multiple periungual ﬁbromas, shagreen patches over her lower
back, and hypomelanotic macules (ash leaf) over the left side of her
waist (Fig. 1). The boy’s family history revealed that his 17-year-old
brother was also affected by TSC with facial angioﬁbromas, a left
index ﬁnger periungual ﬁbroma, shagreen patches over the right
lower abdomen, and de-pigmented lesions over the left lower back.
Both the mother and the elder brother had their tuberous sclerosis
1 (TSC1) gene sequenced directly from peripheral blood leukocytermatological features of tuberous sc
, Buddhist Tzu Chi General
alien, Taiwan. Tel.: þ886
).
ddhist Compassion Relief Tzu ChiDNA. Sequencing revealed a T to C point mutation over the TSC1
gene at exon 6, codon 482, causing an amino acid change from
leucine to proline (TSC1 c.482 T>C CTG>CCG Leu>Pro) (Fig. 2).
High resolution melting (HRM) curve analysis of the TSC1 gene also
revealed a nucleotide T to C mutation in codon 482 (Fig. 3) from the
mother and elder brother’s peripheral blood leukocyte DNA. This
mutated single nucleotide substitution has not been previously
reported.
The boy did not have any dermatologic features of TSC and no
cardiac murmur was found. In addition, no history of learning
disabilities or seizures was reported. Typically, hypomelanoticlerosis complex in the patient's mother.Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 2. Tuberous sclerosis 1 (TSC1) gene direct sequencing analysis reveals a T to C
point mutation over codon 482 causing an amino acid change from leucine to proline
(TSC1 c.482 T>C CTG>CCG Leu>Pro mutation). WT ¼ wild type; TSC132-1 ¼ mother;
TSC132-2 ¼ elder brother.
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neurocutaneous manifestations, including angioﬁbromas, occur
before the age of nine. Therefore, psychological support was offered
to themother during the genetic counseling process to alleviate herFig. 3. High resolution melting (HRM) curve analysis of the tuberous sclerosis 1 (TSC1) gene
from both mother and elder brother.)concerns. In addition, genetic counseling for the whole family was
encouraged to aid in understanding the clinical characteristics of
TSC, disease hereditability, and coping strategies for the disease. It
was decided that genetic testing would be postponed until the boy
reached the age of full decision-making ability.
Recently, tremendous knowledge about molecular genetics has
emerged and many genetic testing methods have been rapidly
introduced into clinical practice. This change presents many
challenges to social policy and to health care ethics. Genetic testing
in pediatric patients poses an especially great concern because of
the lack of decision-making ability of the patient and parental
involvement.
For genetic counseling, the provision of comprehensive infor-
mation about the disease, the limitations in knowledge, and the
available treatment options to the parent is mandatory. It is also
important to address the potential psychological harm, stigmati-
zation, and discrimination that acquisition of certain genetic
information may cause. The American Academy of Pediatrics does
not support the broad use of carrier screening in children and
adolescents. In the absence of clearly beneﬁcial treatments or
effective preventative methods, it may be preferable to defer
genetic testing of children or adolescents. Genetic testing for late-
onset genetic disorders should be individualized during the
genetic counseling process and should be withheld until adulthood
or until mature decision-making capacity has developed. The ethics
committee at the speciﬁc health care organization may also be
consulted in controversial cases.Further reading
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